Cleerly ISCHEMIA vs vascuCAP
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 70/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (Cleerly ISCHEMIA) focuses on non-invasively determining the likelihood of coronary artery ischemia and estimating fractional flow reserve from CCTA scans. Tool B (vascuCAP) specializes in quantifying plaque composition and assessing cardiovascular risk for stroke and heart attack through CT angiography analysis. While both analyze cardiac CT scans and characterize plaque, Cleerly ISCHEMIA is geared towards functional assessment of blood flow, whereas vascuCAP prioritizes detailed plaque vulnerability and future event risk stratification.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Cleerly ISCHEMIA primarily focuses on non-invasively determining the likelihood of coronary artery ischemia at a vessel level, including non-invasive fractional flow reserve (FFR) estimation, to aid in personalized diagnosis and treatment planning for heart disease. In contrast, vascuCAP (now ElucidVivo/PlaqueIQ) is designed to quantify plaque composition and assess broader cardiovascular risk for stroke and heart attack.
Cleerly ISCHEMIA provides coronary plaque characterization by volume, type, and location, along with stenosis severity assessment. vascuCAP offers histologically-validated plaque quantification and characterization, specifically quantifying components like lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage.
Cleerly ISCHEMIA aids in personalized diagnosis and treatment planning for heart disease by determining ischemia likelihood and assessing coronary artery disease. vascuCAP specifically focuses on risk stratification for stroke and heart attack through its detailed plaque assessment and quantification of plaque components.
vascuCAP explicitly states that its plaque quantification and characterization are histologically-validated. Cleerly ISCHEMIA's algorithm uses measurements based on invasive FFR data to determine the likelihood of vessel-level ischemia and has demonstrated diagnostic accuracy in clinical trials.
Cleerly ISCHEMIA provides non-invasive fractional flow reserve (FFR) estimation and vessel-level ischemia likelihood determination. vascuCAP quantifies specific plaque components such as lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage.
Both tools require contacting their respective companies for detailed pricing information. However, Cleerly ISCHEMIA specifies that its Cleerly Proxy service, used for data transfer, is provided without additional charge to clients of the Cleerly service.
More Comparisons
Backers
Who funded each tool's parent company.